Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Orexo AB    ORX   SE0000736415

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Orexo : Interim report January-March 2014

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2014 | 08:14am CEST

Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2013.

Zubsolv®, now with broader market access

First quarter 2014

  • Total net revenues amounted to MSEK 101.9 (139.8). Revenues from launched products, excluding one-off milestone, amounted to MSEK 101.9 (72.1).
  • Earnings after tax were MSEK -21.1 (27.5).
  • Earnings per share were SEK -0.66 (0.95).
  • Cash flow from operating activities amounted to MSEK -99.7 (-5.0).
  • Cash and cash equivalents amounted to MSEK30.7 (218.9) before non-utilized credit facilities of MSEK 105.
  • Reimbursement agreement for Zubsolv signed with UnitedHealth Group and OptumRx.

After the period

  • Orexo has engaged Pareto Securities to investigate the market regarding issuance of a corporate bond. Proceeds would be used to finance the continued development and commercialization of Zubsolv and to reduce the existing bank debt.
MSEK 2014 2013 2013
Jan-Mar Jan-Mar Jan-Dec
Net revenues 101.9 139.8 429.4
Revenues from launched products 101.9 136.4 421.6
EBIT -16.2 30.2 -139.7
EBITDA -13.7 31.5 -89.1
Earnings after tax -21.1 27.5 -154.9
Earnings per share, SEK -0.66 0.95 -5.16
Cash flow from operating activities -99.7 -5.0 -265.8
Cash and cash equivalents 30.7 218.9 105.6

CEO Nikolaj Sørensen and CFO Henrik Juuel will present the report at a teleconference today on two occasions:
9:00am CET
Telephone: SE: +46 8 519 993 61, UK: +44 20 319 405 54 or US: +1 855 269 26 07

2:00pm CET
Telephone: SE: +46 8 519 993 55, UK: +44 20 319 405 50 or US: +1 855 269 26 07

For further information, please contact:
Nikolaj Sørensen, CEO or Henrik Juuel, EVP and CFO
Tel: +46 (0)18 780 88 00, E-mail: [email protected]

CEO's comments
During the quarter, Orexo's focus has been to continue to improve the reimbursement status of Zubsolv. I am pleased to see that our dedication and efforts continue to pay off, with the announcement of an exclusive agreement with the largest insurance company in the USA, UnitedHealth Group. This agreement makes Zubsolv the only buprenorphine/naloxone product available to patients within UnitedHealth Group's highly controlled plans.

During the quarter, sales of Zubsolv doubled compared to the end of 2013, as a result of the brand exclusivity agreement with CVS Caremark and Medimpact. With this improved reimbursement, level we restricted the terms of the patient support program in order to increase the profitability of each prescription. As a result, the number of tablets per script nearly doubled within a few weeks, which temporarily slowed the growth of prescriptions week on week, but had a very positive impact on sales.

Improving reimbursement is currently the single most important commercial initiative to reach more patients. Zubsolv is clearly benefiting from being reimbursed in parity with or better than our competitors and we continue to work intensively to improve this position further. In addition to UnitedHealth Group, we have during the period either signed agreements or secured reimbursement improvements with several regional plans where Zubsolv has not previously been reimbursed. For example these plans cover patients located in the metro-Philadelphia area, Pittsburgh vicinity and across Ohio. The regional plans are, on a nationwide scale, smaller but they are critical to gain market leadership in high value concentrated U.S. geographies. The improvement of regional coverage will continue during the second quarter and I expect that this will start to have an effect on sales from late in the second quarter, in parallel with the agreement with UnitedHealth Group.

As a result of what we have learned during the initial launch period, the sales force has been restructured during the first quarter. We have increased the number of representatives in some areas with good market access, and replaced a part of the sales force with representatives having a higher competency and experience profile relative to the addiction specialty field. This restructuring has led to a typical disruption in sales force performance, but we have also experienced territories where sales representatives with a consistent visit frequency and selling approach in their calls clearly are achieving better results. Therefore, we are monitoring and working closely with our partner Publicis Touchpoint Solutions to improve the sales force performance and ability to impact prescriptions.

We continue to work hard to strengthen the differentiation of Zubsolv, and the three new clinical studies ongoing are expected to improve our dialogue with prescribers and increase confidence in Zubsolv and Orexo as the first results become available this summer. We are also working intensively to broaden our dosage range offerings.

Zubsolv is still in a launch mode and I expect the sales development to improve in a stepwise fashion as reimbursement improves and as the results of our clinical trials become available. We are well on track to reach our competitive reimbursement target level for Zubsolv. I am optimistic that this together with our highly dedicated US and SE organization, will enhance the conditions for strong sales growth in 2014.

Nikolaj Sørensen
President and CEO

Please note
Orexo AB publ discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Market Act. The information was provided for public release on April 25, 2014, at 8:00 a.m. This report has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall prevail.

The following files are available for download:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on OREXO AB
04/26OREXO : Interim Report Q1 2018
04/20OREXO : Invitation to presentation of Orexo´s Interim Report Q1 2018 on April 26
04/12OREXO : Report from Orexo AB’s annual general meeting
04/12OREXO : Report from Orexo AB's annual general meeting
03/22OREXO : publishes the Annual Report for 2017
03/08OREXO : Notice of Annual General Meeting of Orexo
02/06OREXO : participating in new project concerning R&D for Drug Delivery technologi..
01/31OREXO : Number of shares and votes in Orexo
01/25OREXO : Full Year Report incl. Q4 2017
01/23OREXO : Invitation to presentation of Orexo´s Q4 and Full Year Report 2017
More news
News from SeekingAlpha
01/25Orexo AB ADR 2017 Q4 - Results - Earnings Call Slides 
01/25Orexo AB reports Q4 results 
2017Orexo AB reports Q2 results 
2017Orexo AB reports Q1 results 
2017Orexo AB reports Q4 results 
Financials ( SEK)
Sales 2018 741 M
EBIT 2018 113 M
Net income 2018 80,1 M
Finance 2018 87,5 M
Yield 2018 -
P/E ratio 2018 15,74
P/E ratio 2019 12,93
EV / Sales 2018 1,60x
EV / Sales 2019 1,37x
Capitalization 1 274 M
Duration : Period :
Orexo AB Technical Analysis Chart | ORX | SE0000736415 | 4-Traders
Technical analysis trends OREXO AB
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 42,0  SEK
Spread / Average Target 16%
EPS Revisions
Nikolaj Sørensen President & Chief Executive Officer
Alf Gunnar Martin Nicklasson Chairman
Jesper Lind Chief Operating Officer
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Michael Sumner Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OREXO AB-12.14%147
ABBVIE9.84%168 177
MERCK KGAA-5.29%12 941